Here, we tested the hypothesis that metabolic stress induces breast cancer stem-like cell (BCSC) phenotype in triple-negative breast cancer (TNBC).Flow cytometry for GD2 expression, mass spectrometry and Ingenuity Pathway Analysis for metabolomics, bioinformatics, in vitro tumorigenesis and in vivo ...
18,19] by favoring cancer cell stem-like [20] and EMT properties [7,21,22], especially in breast cancer [23], and it supports metastasis formation by increasing plasticity, cell motility [12] and resistance to detachment-induced cell death. Interestingly, Snai2 knockdown results in reduced i...
Triple Negative Breast Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in triple negative breast cancer clinical trials today.
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of ...
Triple negative breast cancer is more often responsive to chemotherapy than hormone receptor positive (ER+/PR+) breast cancer. On the other hand, long-term hormonal treatments (tamoxifen, aromatase inhibitors) used for ER+ subtypes are not effective for triple negative breast cancer since estrogen ...
TNBC, triple-negative breast cancer; pCR, pathological complete response; mRNA, messenger RNA; LABC, locally advanced breast cancer; 5-FU, 5-fluorouracil; ORR, overall response rate; G-CSF, granulocyte colony-stimulating factor; DFS, disease-free survival; N, neoadjuvant; M, metastatic; CR, ...
University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments for triple-negative breast cancer.
Breast Cancer: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins Jing Ma1, Chao Dong...
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor prognosis due to the lack of therapeutic targets. Although immunotherapy brings survival benefits to patients diagnosed with TNBC, it remains limited and treatment resistance is widespread. Here we demonstrate...
Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we report the final results of FUTURE, a phase II umbrella tria